Last reviewed · How we verify
Beclomethasone and Salbutamol
This combination inhaler delivers a corticosteroid (beclomethasone) to reduce airway inflammation and a short-acting beta-2 agonist (salbutamol) to rapidly relieve bronchospasm.
This combination inhaler delivers a corticosteroid (beclomethasone) to reduce airway inflammation and a short-acting beta-2 agonist (salbutamol) to rapidly relieve bronchospasm. Used for Asthma maintenance and acute symptom relief, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone and Salbutamol |
|---|---|
| Also known as | Clenil Compositum |
| Sponsor | University of Calgary |
| Drug class | Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) |
| Target | Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Beclomethasone is a topical corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salbutamol is a selective beta-2 adrenergic agonist that activates beta-2 receptors on airway smooth muscle, causing rapid bronchodilation. Together, they provide both anti-inflammatory control and acute symptom relief in asthma and COPD.
Approved indications
- Asthma maintenance and acute symptom relief
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Nervousness
Key clinical trials
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (Full Study) (PHASE4)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma (PHASE2)
- Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis (EARLY_PHASE1)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- Non-invasive Measures of Distal Lung Disease in Asthmatics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclomethasone and Salbutamol CI brief — competitive landscape report
- Beclomethasone and Salbutamol updates RSS · CI watch RSS
- University of Calgary portfolio CI